235 related articles for article (PubMed ID: 36165864)
1. Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel.
Salvati A; Carnevali I; Alexandrova E; Facchi S; Ronchi S; Libera L; Sahnane N; Memoli D; Lamberti J; Amabile S; Pepe S; Tarallo R; Sessa F; Weisz A; Tibiletti MG; Rizzo F
Exp Mol Pathol; 2022 Oct; 128():104833. PubMed ID: 36165864
[TBL] [Abstract][Full Text] [Related]
2. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
3. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
4. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract][Full Text] [Related]
7. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
[TBL] [Abstract][Full Text] [Related]
9. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract][Full Text] [Related]
10. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
12. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
16. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes.
Shah S; Cheung A; Kutka M; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805770
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
[TBL] [Abstract][Full Text] [Related]
18. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732
[TBL] [Abstract][Full Text] [Related]
19. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
20. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
